Los Alamos hepatitis C immunology database

Applied Bioinformatics

Volumn 4, Issue 4, 2005, Pages 217-225

  Yusim, Karina ^a   Richardson, Russell ^a   Tao, Ning ^a   Dalwani, Anita ^a   Agrawal, Ashish ^a   Szinger, James ^a   Funkhouser, Robert ^a   Korber, Bette ^a   Kuiken, Carla ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS C VACCINE; INTERFERON; RIBAVIRIN; T LYMPHOCYTE ANTIGEN; VIRUS PROTEIN;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; DATA BASE; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE SYSTEM; NUCLEOTIDE SEQUENCE; VIRUS MUTATION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 28444473437     PISSN: 11755636     EISSN: 11755636     Source Type: Journal    
DOI: 10.2165/00822942-200504040-00002     Document Type: Article

References (37)

1. World Health Organization. Hepatitis C. Fact sheet no. 164 [online]. October 2000. Available from URL: http://www.who.int/mediacentre/factsheets/ fs164/en/print.html [Accessed 2005 Nov 3]
2. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of communityacquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-905
3. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S
4. Krahn M, Wong JB, Heathcote J, et al. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004; 24: 20-9
5. Grakoui A, Hanson HL, Rice CM. Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis. Hepatology 2001; 33: 489-95
6. Lanford RE, Bigger C. Advances in model systems for hepatitis C virus research. Virology 2002; 293: 1-9
7. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003; 59: 1-11
8. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004; 6: 66-70
9. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62
10. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-500
11. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994; 91: 7792-6
12. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995; 208: 653-61
13. Ishii K, Rosa D, Watanabe Y, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998; 28: 1117-20
14. Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci 2003; 28: 287-304
15. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601
16. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-49
17. Cucchiarini M, Kammer AR, Grabscheid B, et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 2000; 203: 111-23
18. Darling JM, Wright TL. Immune responses in hepatitis C: is virus or host the problem? Curr Opin Infect Dis 2004; 17: 193-8
19. Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883-95
20. Gruner NH, Gerlach TJ, Jung MC, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 1528-36
21. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-512
22. Ward S, Lauer G, Isba R, et al. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128: 195-203
23. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-41
24. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20: 103-26
25. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354-60
26. Kuiken C, Yusim K, Boykin L, et al. The Los Alamos hepatitis C sequence database. Bioinformatics 2005 Feb 1; 21 (3): 379-84
27. Korber B, Brander C, Haynes B, et al. HIV molecular immunology 2002. Los Alamos (NM): Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2003
28. Rolsky D, Williams K. Embedding Perl in HTML with Mason. Sebastopol (CA): O'Reilly & Associates Inc., 2003
29. Wall L, Christiansen T, Orwant J. Programming Perl. Sebastopol (CA): O'Reilly & Associates Inc., 2000
30. Stajich JE, Block D, Boulez K, et al. The Bioperl toolkit: Perl modules for the life sciences. Genome Res 2002; 12: 1611-8
31. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76: 8757-68
32. Los Alamos National Laboratory. Hepatitis C Virus (HCV) Immunology Database [online]. Available from URL: http://hcv.lanl.gov or http://hcv-db.org [Accessed 2005 Nov 3]
33. Calef C, Thakalapally R, Lang D, et al. PeptGen: designing peptides for immuno-logical studies and application to HIV consensus sequences. In: Korber BT, Brander C, Haynes B, et al., editors. HIV molecular immunology 2000. Los Alamos (NM): Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2000: I63-7
34. Thakalapally R, Kibbe W, Lang D, et al. MotifScan: a web-based tool to find HLA anchor residues in proteins or peptides. In: Korber B, Brander C, Haynes B, et al., editors. HIV molecular immunology database 2000. Los Alamos (NM): Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2000: I-101-102. Report no.: LA-UR 02-2877
35. Yusim K, Szinger J, Honeyborne I, et al. Enhanced MotifScan: a tool to scan for HLA anchor residues in proteins, HIV molecular immunology 2003. Los Alamos (NM): Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2004: 25-36
36. Calef C, Thakalapally R, Kaslow R, et al. ELF: an analysis tool for HIV-1 peptides and HLA types. In: Korber B, Brander C, Haynes B, et al., editors. HIV molecular immunology 2001. Los Alamos (NM): Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2001: I-21-25. Report no.: LA-UR 02-2877
37. Sarobe P, Jauregui JI, Lasarte JJ, et al. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. J Hepatol 1996; 25: 1-9